Curaleaf Holdings, Inc. (OTCMKTS:CURLF - Free Report) - Equities researchers at Roth Capital issued their FY2024 earnings per share estimates for shares of Curaleaf in a report released on Sunday, November 10th. Roth Capital analyst W. Kirk expects that the company will earn ($0.26) per share for the year. Roth Capital currently has a "Strong-Buy" rating on the stock. The consensus estimate for Curaleaf's current full-year earnings is ($0.25) per share. Roth Capital also issued estimates for Curaleaf's Q4 2024 earnings at ($0.07) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS and FY2025 earnings at ($0.21) EPS.
Several other brokerages have also commented on CURLF. Cormark lowered Curaleaf from a "moderate buy" rating to a "hold" rating in a research note on Thursday, November 7th. Needham & Company LLC restated a "buy" rating and set a $6.25 target price on shares of Curaleaf in a research report on Thursday, August 8th.
Get Our Latest Report on CURLF
Curaleaf Price Performance
OTCMKTS CURLF traded up $0.20 during trading hours on Wednesday, hitting $2.24. 1,374,771 shares of the company's stock traded hands, compared to its average volume of 714,002. Curaleaf has a 52-week low of $1.64 and a 52-week high of $6.40. The company has a quick ratio of 0.51, a current ratio of 1.11 and a debt-to-equity ratio of 0.85. The firm's 50-day moving average is $2.93 and its 200-day moving average is $3.75.
Curaleaf Company Profile
(
Get Free Report)
Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.
Read More
Before you consider Curaleaf, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Curaleaf wasn't on the list.
While Curaleaf currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
